Whether you’re looking to invest in the stock market or have been a part of the stock market for years, you’ll find that Clover stock is a great option. The company is a healthcare provider that provides Medicare Advantage insurance plans and operates as a direct contracting entity for the U.S. government. As a result, it has been a popular choice among many investors.
Market cap
Getting a good sense of the Market cap of a CLOV stock is an essential part of making informed investment decisions. The market cap calculates the company’s value based on its stock price and the number of outstanding shares. The market cap is also a measure of the estimated value of common equity securities. Some “novice” investors use the market cap to compare stocks at different prices. However, these comparisons are meaningless without understanding the numbers involved.
The market cap of Clover Health Investments (CLOV) is a modest $0.58 billion in December 2022. It has a total of 477,943,748 outstanding shares. The company operates as a direct contracting entity of the U.S. government and offers Medicare Advantage insurance plans.
Earnings
During the earnings season, investors will be looking for information on earnings for Clov stock. The company provides Medicare Advantage insurance plans and operates as a direct contracting entity in the United States. The company is expected to report earnings between February 22, 2023, and February 24, 2023. The last time CLOV reported earnings, after the market closed was November 7, 2022. The company held a conference call for investors at 5:00 PM Eastern on the same day.
The Earnings Estimates page shows analyst estimates for the current year and the next two quarters. The table also shows how many analysts contribute estimates and the group’s average and high/low estimates. The table is updated after the company announces its actual earnings date.
Technicals
Using technicals to assess a stock’s performance is a must for anyone looking to buy and sell. Luckily, there are several tools at your disposal. The Relative Strength Index (RSI) is the most common, which measures the speed of price movements. The RSI has an approximate range of zero to 100. When the reading is below 30, the stock is considered oversold.
For example, it is worth noting that Clover Health Investments Corp.’s (CLOV) stock has lost 22.2% in the last four weeks. The NASDAQ has also declined 28% over the same period, while the S&P 500 has fallen by 17 percent. That is a lot of change, so why is the company’s stock losing ground?
While the company does offer insurance plans to Medicare Advantage members, it is not a traditional stock brokerage. Instead, it operates as a healthcare plans business in the U.S. The firm employs 680 people and has a trailing twelve-month revenue of approximately $3 billion.
Getting an up close and personal look at Clover Health Investments (CLOV) stock is a treat for those with a pulse. The company has been in the healthcare technology business for over a decade. It uses a proprietary technology platform to analyze health data and develop products and services to address the thorny medical device industry. With that in mind, it’s essential to understand the company’s share count. But, of course, you should also be aware that the company’s total outstanding shares are not equal.
A quick calculation of CLOV’s stock count should reveal a tidbit: a whopping 476,061,809 common shares are kicking around. This figure comprises just over half of the company’s Class A common stock and more than a quarter of its Class B common stock.
Key takeaways
During the last quarter, Clover Health (CLOV) saw an impressive increase in its Medicare Advantage “M.A.” membership. The number of members grew by 17.3%, in line with historical growth rates. In addition, the Medical Cost Ratio (MCR) decreased to 102.8% from 109.3%, assuaging fears of the company selling its plans at a loss. The Q4 earnings release also improved MCR guidance between 95% and 99%.
CLOV was backed by Chamath Palihapitiya, an investor and entrepreneur passionate about bringing technology and healthcare to the masses. His thesis was that artificial intelligence and technology would help bring down medical costs. However, technology has not been able to deliver on this promise. COVID disruptions have hit the firm’s profitability margins.
